---
title: "ZVRA: Q2 revenue up 53% to $39.7M, driven by MIPLYFFA growth and robust cash position of $260.2M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295026314.md"
description: "Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-05T22:46:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295026314.md)
  - [en](https://longbridge.com/en/news/295026314.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295026314.md)
generator: "portal-rs"
---

# ZVRA: Q2 revenue up 53% to $39.7M, driven by MIPLYFFA growth and robust cash position of $260.2M

Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md)

## Related News & Research

- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35](https://longbridge.com/en/news/295278479.md)
- [Trump is waging a war on America's children — and he's winning](https://longbridge.com/en/news/298133228.md)
- [Ionis: FDA approves ZANVASTRO for Alexander disease, pivotal study shows 33.3% gait stabilization](https://longbridge.com/en/news/298024012.md)
- [Wall Street Grilled This CEO on Whether AI Growth Is Real or Just Hype — Here’s What He Said as the Stock Popped 23%](https://longbridge.com/en/news/297885681.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**